Study on the Therapeutic Benefit on Lactoferrin in Patients with Colorectal Cancer Receiving Chemotherapy

Table 4

Effect of oral administration of bLF on patients in test group after 3 months (results represented as mean ± SD values).

Parameter	Control; mean ± SD	LF; mean ± SD
BUN (mg/dL)	0.3 ± 2.9	4.8 ± 3.14^*
Serum creatinine (mg/dL)	0.078 ± 0.22	0.14 ± 0.26^*
AST (IU/L)	0.306 ± 7.29	12.44 ± 13.22^*
ALT (IU/L)	0.88 ± 5.4	6.88 ± 11.27^*
Serum LF (ng/mL)	0.002 ± 0.011	0.15 ± 0.16^*
Serum GST enzyme (ng/mL)	0.000 ± 0.002	0.206 ± 0.089^*
INF-γ (pg/mL)	0.1 ± 0.27	1.62 ± 0.66^*
WBCs (*10^3 cell/µL)	0.146 ± 0.727	1.06 ± 1.18^*
Platelet (*10^3/mm^3)	25.40 ± 39.06	36.46 ± 12.26^*
CEA (ng/mL)	8.37 ± 23.91	13.41 ± 21.91^*
RBCs (*10^6/µL)	0.111 ± 0.222	0.514 ± 0.126^*
Neutrophil (%)	0.93 ± 4.7	11.86 ± 1.45^*
Hb (g/dL)	0.52 ± 1.2	1.97 ± 0.35^*

Note: ^*significant difference .